Wednesday, May 15, 2019

Myovant Sciences Ltd said on Tuesday its combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids.


from Reuters: Health News https://reut.rs/2PZY9Ll

Related Posts:

  • LATEST HEALTH NEWS(Reuters Health) - Being one of the youngest in a kindergarten class dramatically increases the odds that a child will be diagnosed and treated for attention deficit-hyperactivity disorder(ADHD), a large new U.S. study has co… Read More
  • LATEST HEALTH NEWSHe Jiankui had told a packed biomedical conference he was 'proud' to have successfully altered the DNA of twin girls born to an HIV-positive father from Health https://ift.tt/2KFLL08 … Read More
  • LATEST HEALTH NEWS(Reuters Health) - Despite improved survival rates for many cancers, a diagnosis can still be very distressing and may raise a patient's risk of suicide, researchers say. from Reuters: Health News https://ift.tt/2BDMlZD … Read More
  • LATEST HEALTH NEWSTobacco giant Altria Group Inc is in talks to take a significant minority stake in e-cigarette maker Juul Labs Inc, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. from Reuters: Hea… Read More
  • LATEST HEALTH NEWS(Reuters Health) - - Many older drivers are taking multiple medications that may increase the risk of car crashes, a new U.S. study suggests. from Reuters: Health News https://ift.tt/2DNyRvQ … Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner